“We conclude that these collective results suggest that canagliflozin may improve adipose tissue function, increasing adiponectin and decreasing the inflammatory posture of the adipocytes as reflected by a decrease in IL-6, independent of weight loss, and these may reflect favorably on cardiometabolic health.”
